AMRN jackpot keeps on getting bigger. Possible Diabetes secondary endpoints.
Dr. Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School, Executive Director of Interventional Cardiovascular Programs in the Heart and Vascular Center at Brigham and Women's Hospital, and the Principal Investigator and Steering Committee Chair for REDUCE-IT will be presenting at the CardioMetabolic Health Congress (CMHC) on October 25th in Boston. The session is from 8 to 930 and is on FDA update on late breaking clinical study related to Diabetes Managemen
Dr. Deepak L. Bhatt, MD, MPH, Professor of Medicine at Harvard Medical School, Executive Director of Interventional Cardiovascular Programs in the Heart and Vascular Center at Brigham and Women's Hospital, and the Principal Investigator and Steering Committee Chair for REDUCE-IT will be presenting at the CardioMetabolic Health Congress (CMHC) on October 25th in Boston. The session is from 8 to 930 and is on FDA update on late breaking clinical study related to Diabetes Managemen
@KING WILL how'd you get the drop on AMRN when it was at $12? Got any good sources that you can share? Feel free to PM.
I'm all over a few investment blogs and sites and didn't see much on it until recently
I'm all over a few investment blogs and sites and didn't see much on it until recently
YouTube Video's, Stocktwits, Yahoo Finance, Seeking Alpha (sign up and they send you lots of emails), I recently started going to the FDA site to for cheap, medical stocks. It might be 1, or 2 that I missing, but I spend most of my time on the 1st 3 I mentioned.
I think I seen AMRN trending on Stocktwits. I read the reason it was trending and how people were reacting, so I sold off some AMD shares, then waiting for ARMN to dip a lil bit, and made my purchase. Got In at $9 that day, and it closed at $12.
W/ more and more talk of a buyout, I might sell off some more shares of AMD after its ER and get more shares of AMRN.
I forgot the company, but I seen 1 company trending the other day and that shyt was up almost 600% on the day. Too bad it was EOD and I couldn't get a lil bump.
What sites are you using?
That's dope man. I'm gonna check out stocktwits, haven't used that. I've been using Seeking Alpha, Investor Place, and the Seville Report as main info sources, plus a couple of twitter accounts
Tug life
I stay fly like a guillemot
I knew October would be volatile but damn 
i dont want to look at my portflio for the rest of the month its a bloodbath 
i dont want to look at my portflio for the rest of the month its a bloodbath 
Rickdogg44
RIP Charmander RIP Kobe
What caused the hype? Saw sec halting it
1.If you speak to any competent physician, they say that Diabetes is actually a reflection of a cardio-vascular problem. The high blood sugar is only a symptom of it.
2. From a doctor on another board, (paraphrasing), it's inflammation that prevents insulin from doing what its supposed to do. It is also inflammation that causes high trigs in non-diabetics and diabetics, as well. Vascepa reduces inflammation, which allows the body to process (insulin) properly and triglycerides drop. This is why this drug is so valuable. Reducing inflammation reduces triglycerides and lowers MACE, and will also allow insulin to do its job in diabetics, but Vascepa will also reduce inflammation in countless other ways... Seborrheic dermatitis? Rheumatoid Arthritis? Scarring after surgery? Rosacea? Will it affect the mechanisms of Alzheimers? Parkinsons? Multiple Sclerosis? How many other countless applications will/does it have?
3. News: Vascepa helped diabetes patients: CREATES SHORT-LONG CRISIS, Stockvadar-writes
Like it or not, Amarin's lead investigator is reporting this week to a room of cardio-diabetes specialists.
Go long or go short, your money. We believe Vascepa helped diabetes patients.
Let it sink in. $60B is our baseline (probably low) for a buy-out.
-sv (STRONG BUY)
2. From a doctor on another board, (paraphrasing), it's inflammation that prevents insulin from doing what its supposed to do. It is also inflammation that causes high trigs in non-diabetics and diabetics, as well. Vascepa reduces inflammation, which allows the body to process (insulin) properly and triglycerides drop. This is why this drug is so valuable. Reducing inflammation reduces triglycerides and lowers MACE, and will also allow insulin to do its job in diabetics, but Vascepa will also reduce inflammation in countless other ways... Seborrheic dermatitis? Rheumatoid Arthritis? Scarring after surgery? Rosacea? Will it affect the mechanisms of Alzheimers? Parkinsons? Multiple Sclerosis? How many other countless applications will/does it have?
3. News: Vascepa helped diabetes patients: CREATES SHORT-LONG CRISIS, Stockvadar-writes
Like it or not, Amarin's lead investigator is reporting this week to a room of cardio-diabetes specialists.
Go long or go short, your money. We believe Vascepa helped diabetes patients.
Let it sink in. $60B is our baseline (probably low) for a buy-out.
-sv (STRONG BUY)
This is the ultimate cause of the continued excitement about the stock in front of what we have pegged the “next big day” for the stock, which is November 10 – that is when we will get the company’s presentation of its full Vascepa data for the scientific sessions meeting of the American Heart Association.
What’s at Stake for Amarin Corporation plc (NASDAQ:AMRN) as the Next Big Day Looms - FDA Headlines
What’s at Stake for Amarin Corporation plc (NASDAQ:AMRN) as the Next Big Day Looms - FDA Headlines